ZyVersa Therapeutics, Inc. (ZVSA)

ZyVersa Therapeutics, Inc. is a biopharmaceutical company developing therapeutic treatments for inflammatory and renal diseases. The company is advancing IC 100, a monoclonal antibody targeting inflammasome-related inflammation, and VAR 200, a cholesterol efflux mediator designed to address cholesterol accumulation in kidney filtration systems.